ImmuCell Corporation is a biotechnology business based in the US. ImmuCell Corporation shares (ICCC) are listed on the NASDAQ and all prices are listed in US Dollars. ImmuCell Corporation employs 64 staff and has a trailing 12-month revenue of around $20.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $7.71 |
|---|---|
| 52-week range | $6.96 - $10.96 |
| 50-day moving average | $8.17 |
| 200-day moving average | $8.51 |
| Wall St. target price | $14.00 |
| PE ratio | 192.75 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.71 from 2022-09-23
| 1 week (2022-09-19) | -3.38% |
|---|---|
| 1 month (2022-08-26) | -0.77% |
| 3 months (2022-06-24) | -8.32% |
| 6 months (2022-03-25) | -23.36% |
| 1 year (2021-09-24) | -20.43% |
|---|---|
| 2 years (2020-09-25) | 40.44% |
| 3 years (2019-09-26) | 41.73% |
| 5 years (2017-09-26) | 22.38% |
Valuing ImmuCell Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ImmuCell Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ImmuCell Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 193x. In other words, ImmuCell Corporation shares trade at around 193x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ImmuCell Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 million.
The EBITDA is a measure of a ImmuCell Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $20.5 million |
|---|---|
| Operating margin TTM | 2.89% |
| Gross profit TTM | $8.7 million |
| Return on assets TTM | 0.82% |
| Return on equity TTM | 0.84% |
| Profit margin | 1.34% |
| Book value | $4.23 |
| Market capitalisation | $59.7 million |
TTM: trailing 12 months
We're not expecting ImmuCell Corporation to pay a dividend over the next 12 months.
ImmuCell Corporation's shares were split on a 1:100 basis on 24 July 1990. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmuCell Corporation shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ImmuCell Corporation shares which in turn could have impacted ImmuCell Corporation's share price.
Over the last 12 months, ImmuCell Corporation's shares have ranged in value from as little as $6.96 up to $10.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmuCell Corporation's is 0.6256. This would suggest that ImmuCell Corporation's shares are less volatile than average (for this exchange).
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.